(Q37984087)

English

Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists

scientific article published on 16 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

substance dependence

0 references

0 references

0 references

cannabinoid receptor

0 references

author name string

David R Janero

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

language of work or name

0 references

publication date

16 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Expert Opinion on Emerging Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

17-29

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The endocannabinoid system in brain reward processes

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The endocannabinoid system and nondrug rewarding behaviours

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Common cellular and molecular mechanisms in obesity and drug addiction

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

New horizons for therapeutics in drug and alcohol abuse

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

When simple agonism is not enough: emerging modalities of GPCR ligands.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Theme and variations on kinetics of GPCR activation/deactivation

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Endocannabinoid tone versus constitutive activity of cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Inverse agonism and neutral antagonism at cannabinoid CB1 receptors

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Inhibitory effects of SR141716A on G-protein activation in rat brain

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Methamphetamine neurotoxicity increases brain expression and alters behavioral functions of CB₁ cannabinoid receptors.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid receptor 1 gene association with nicotine dependence

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid agonist-induced sensitisation to morphine place preference in mice

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Subchronic cannabinoid agonist (WIN 55,212-2) treatment during cocaine abstinence alters subsequent cocaine seeking behavior.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

AM 251 differentially effects food-maintained responding depending on food palatability.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Effects of CB1 receptor antagonist within the nucleus accumbens on the acquisition and expression of morphine-induced conditioned place preference in morphine-sensitized rats.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

SLV330, a cannabinoid CB(1) receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Acute blockade of CB1 receptor leads to reinstatement of MDMA-induced conditioned place preference.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Pleiotropic effects of rimonabant: clinical implications

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Randomized, controlled, double-blind trial of taranabant for smoking cessation

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

End of the line for cannabinoid receptor 1 as an anti-obesity target?

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The future of endocannabinoid-oriented clinical research after CB1 antagonists.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Participation of the cannabinoid system in the regulation of emotional-like behaviour

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Impairments in endocannabinoid signaling and depressive illness

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Presence of conspecifics and their odor-impregnated objects reverse stress-decreased neurogenesis in mouse dentate gyrus

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Energy balance regulation by endocannabinoids at central and peripheral levels

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Blood-brain barrier: structural components and function under physiologic and pathologic conditions

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Alterations in blood-brain barrier function by morphine and methamphetamine.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Alteration of blood-brain barrier function by methamphetamine and cocaine

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Alterations in blood-brain barrier function and brain pathology by morphine in the rat. Neuroprotective effects of antioxidant H-290/51.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoids and the gut: new developments and emerging concepts

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

A neutral CB1 receptor antagonist reduces weight gain in rat.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Novel thioamide derivatives as neutral CB1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Endocannabinoids and stress

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Obesity: genes, brain, gut, and environment

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Leptin-regulated endocannabinoids are involved in maintaining food intake

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Animal models of cannabinoid reward

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Zebrafish models to study drug abuse-related phenotypes

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Animal models of neuropsychiatric disorders.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Retrospective. Ralph M. Steinman (1943-2011).

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.660916

21 January 2018

Identifiers

10.1517/14728214.2012.660916

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37984087&oldid=1736316251"